Avalo Therapeutics Inc (AVTX)

Avalo Therapeutics Inc (AVTX) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $728M; returns 1 day -7.0%, 1 week -38.5%, 1 year -61.3%.

Avalo Therapeutics, Inc. (AVTX) is a clinical-stage biotechnology company dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. Their primary focus is on advancing AVTX-009, a humanized monoclonal antibody, through clinical trials, specifically the Phase 2 LOTUS trial for hidradenitis suppurativa (HS), with topline data expected in mid-2026.

Groups AVTX belongs to

• Biotechnology
• Clinical Stage Biotech
• Healthcare
• Clinical Stage
• Monoclonal Antibodies
• Autoimmune Diseases
• Chronic Inflammatory Diseases
• Life Sciences
• Biopharmaceutical
• Antibody Therapeutics

AVTX financial model: income statement, cash flow and balance sheet